Not directly those are not GLP-1 agonists
According to the FDA's official guidance (updated April 2026 at fda.gov), the semaglutide injection shortage was resolved on February 21, 2025, and the transitional exemption windows for compounders operating under the shortage exemption subsequently ended - for 503A pharmacies by April 22, 2025, and for 503B outsourcing facilities by May 22, 2025
The most common are gastrointestinal issues such as nausea, diarrhea and constipation
The compound is supplied here strictly as a research reference standard for in vitro and animal-model investigation, and is not intended for human or veterinary use
LugariRDeiCas AUgolottiDBarilliALCamelliniCGanzerlaGCet al
Taking more than the recommended l-carnitine dosage for weight loss will not speed up fat loss but may lead to mild digestive discomfort